Several immunotherapy protocols, such as immune checkpoint blockade (ICB) with antibodies, have seen significant success in recent years. However, it is clear that these therapies as single modalities or even in combination with each other are only effective for a subset of patients. Additionally, there is growing literature indicating the development of ICB resistance in patients who were previously responsive.
